Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Name: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Published: 2022
License: Public Domain

Genmab · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

cancer

non-hodgkin lymphoma, abbv-gmab-3013, epcoritamab, burkitt's or burkitt-like lymphoma/leukemia, diffuse large b-cell lymphoma, aggressive mature (cd20+) b-cell lymphoma, cancer, relapsed/refractory aggressive mature b-cell neoplasms, epcore, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Related documents